Novartis’ phase III QUARTZ study of new investigational inhaled combination treatment meets primary and key secondary endpoints

Image: Novartis has announced the first study results from the phase III PLATINUM clinical development program assessing the safety and efficacy of QMF149. Photo: courtesy of Novartis AG.